Intranasal Oxytocin for Obesity

Area of Science:

• Endocrinology
• Metabolic Disorders
• Pharmacology

Background:

• Preclinical studies suggest oxytocin aids weight loss by reducing food intake and increasing energy expenditure.
• The efficacy of oxytocin in treating human obesity remains unestablished.

Purpose of the Study:

• To investigate the effectiveness of intranasal oxytocin in treating obesity in adults.
• To evaluate oxytocin's impact on body weight, body composition, energy expenditure, and caloric intake.

Main Methods:

• A randomized, double-blind, placebo-controlled trial involving adults with obesity.
• Participants received intranasal oxytocin (24 IU) or placebo four times daily for 8 weeks.
• Primary endpoint: change in body weight; secondary endpoints: changes in body composition, resting energy expenditure, and caloric intake.

Main Results:

• No significant difference in body weight change was observed between the oxytocin and placebo groups.
• Oxytocin did not show beneficial effects on body composition or resting energy expenditure.
• Oxytocin administration was associated with a reduction in caloric intake during a test meal.

Conclusions:

• Intranasal oxytocin administered for 8 weeks did not result in significant weight reduction in adults with obesity.
• Further research may be needed to explore oxytocin's role in appetite regulation.